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Aims: Parkinson's disease (PD) is a movement disorder that involves non-motor symptoms including cognitive
dysfunction. L-DOPA (L-3,4-dihydroxyphenylalanine), the most effective treatment for PD, might cause the
development of abnormal involuntary movements and psychotic symptoms. It has been argued that a complex
interaction between drug- and intrinsic disease-related components is enrolled in PD psychotic symptoms.
Prepulse inhibition (PPI) is a cross-species measure of sensorimotor gating often disrupted in disorders either
with basal ganglia dysfunction or with psychotomimetic drugs. There are controversial results concerning PPI
in PD patients. Nevertheless, clinical studies are difﬁcult to interpret because of differences in disease severity,
concomitant medications, and comorbidities. Our aim was to investigate the functioning of sensorimotor gating
in the 6-OHDA-inducing partial or complete dopaminergic degeneration of the nigrostriatal pathway.
Main methods: Since several studies suggested that PD-associated psychosis results from interaction between
disease-related factors and dopamine replacement, we also analyzed in rats with complete unilateral lesion of
the nigrostriatal pathway the effect of L-DOPA treatment (30 mg/kg, daily) for 1, 7 or 14 days.
Key ﬁndings: Complete and unilateral dopaminergic striatal depletion disrupted PPI response in rats. In mice,
partial dopaminergic loss in the dorsal striatum, unilateral or bilateral, did not determine PPI changes. L-DOPA
treatment determined either no PPI alteration or PPI increase in the 6-OHDA-lesioned rats.
Signiﬁcance: Complete striatal degeneration induced by 6-OHDA discreetly reproduced the impairment of
PPI found in PD patients. Additionally, L-DOPA at a therapeutical dose, despite adverse motor effects, should
not induce an impairment of sensorimotor response.© 2015 Elsevier Inc. All rights reserved.Introduction
Parkinson's disease (PD) is a progressive movement disorder char-
acterized by resting tremor, bradykinesia and rigidity, resulting mainly
from progressive loss of dopaminergic neurons in the substantia nigra
compacta [24] and reduction of dopamine levels in the striatum [44].
Despite the well-known movement disorder, PD is also character-
ized by cognitive and emotional alterations ([33,58]). Several psychiat-
ric non-motor symptoms might accompany the motor-stages of PD
and comprise depression, psychosis, anxiety and dementia [13,14,19].
Psychosis in PD patients is represented mainly by visual hallucinations
and could appear with the use of dopaminergic medication [16]. The
origin of these symptoms could be related to a complex interaction
between the disease-related components and non-physiologicalool of Odontology, Department
s Ribeirão Preto, SP 14049904,dopamine replacement to reverse motor symptoms [20,23]. The meta-
bolic precursor of dopamine L-DOPA (L-3,4-dihydroxyphenylalanine)
is themost widely used pharmacological agent to enhance the dopami-
nergic signaling in PD [25]. Despite its signiﬁcant improvement of PD
motor symptoms, L-DOPA treatment induces dyskinesia, the most im-
portant side effect usually associated with L-DOPA long-term use [26].
Themalfunctioning of cortico-striato-pallido-thalamic neuronal net-
works determines deﬁcits in the general gating processmechanisms [7].
Several psychopathological patients that exhibit alteration in this brain
circuitry exhibit poor gating of motor, sensory or cognitive information
and corresponding prepulse inhibition (PPI) deﬁcits [7,46]. PPI is amea-
sure of sensorimotor gating and PPI deﬁcits are not unique to a single
pathology [52]. For example, PPI may be altered in basal ganglia disor-
ders including schizophrenia, Tourette's syndrome, and post-traumatic
stress disorder [7,8]. Animalmodels of PPI deﬁcits have been considered
ideal candidates for cross-species translational research [6]. Pharmaco-
logical manipulations in healthy human subjects and rodents produced
similar effects on PPI [52,53]. Precisely, dopamine agonists disrupt PPI in
rodents, and in at least some human studies [7,47,49].
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[59,60]. Animal models may represent an interesting pre-clinical tool
since factors such as disease severity, drug treatment and comorbidities
are easily controlled. Animal models of PD are usually based on the cel-
lular dysfunction and death of dopaminergic neurons of the substantia
nigra induced by toxins, such as 6-hydroxydopamine (6-OHDA), 1-
methyl- 4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone and
paraquat [3,5]. In general, these models reﬂect cardinal symptoms of
PD that include both behavioral and biochemical features [3]. Some
animal models of PD have shown also non-motor features and abnor-
malities outside of the substantia nigra such as abnormal olfactory func-
tion, gastrointestinal problems and sleep disorders ([11] and references
therein).
Based on the hypothesis that abnormalities in cortico-striato-
pallido-thalamic loop may induce sensorimotor deﬁcits, we ﬁrst
aimed to determine how6-OHDA-inducingpartial or complete dopami-
nergic degeneration of the nigrostriatal pathway would inﬂuence
sensorimotor gating using the PPI test to detect such changes. Because
it is likely that PD-associated psychosis may rise from an interaction
between disease-related factors and non-physiological dopamine re-
placement, our second aim was to analyze the effects of early (acute)
and long-term L-DOPA treatment in the PPI test in 6-OHDA-lesioned
rats with severe unilateral lesion of the nigrostriatal pathway.Material and methods
Animals
Adult maleWistar rats (n= 14; 200–250 g; housed in groups of 2-3
per cage) and Swiss albino mice (n= 32; 25–30 g; housed in groups of
5-6 per cage) were used. Animals were maintained in separate rooms,
temperature-controlled (23 ± 1 °C) with a 12/12 h light/dark cycle
with free access to food and water. All experiments were conducted ac-
cording to the principles and procedures described by the Guidelines for
the Care and Use of Mammals in Neuroscience and Behavioral Research
(ILAR, USA). The local Animal Ethics Committee had previously ap-
proved the institution's housing conditions and experimental
procedures.Drugs
Apomorphine hydrochloride (Sigma-Aldrich, St. Louis, MO, USA)
was administered subcutaneously (s.c.; 0.5 mg/kg; 1 ml/kg). In rats,
L-DOPA/benserazide-HCl (Prolopa dispersive, Hoffman-LaRoche,
Brazil) was given orally (gavage, 2 ml/kg), once a day, at the dose of
30/7.5 mg/kg.Fig. 1.Time line of treatments and analyses. The 6-OHDA-induced lesionwas conﬁrmed threew
was evaluated four weeks after the 6-OHDA-induced lesion. Rats were resubmitted to the PPI6-OHDA lesion in the nigrostriatal pathway
The stereotaxic surgery was conducted as previously described [21].
Brieﬂy, rats or mice were anesthetized with a mixture of ketamine
(100 mg/kg) and xylazine (14 mg/kg, both i.p.). In rats, to avoid the
damage of noradrenergic neurons, desipramine hydrochloride
(25 mg/kg i.p., Sigma-Aldrich, St. Louis, MO, USA) was administered
30 min before 6-OHDA injection.
Rats received a single injection of 6-OHDA (Sigma-Aldrich, St. Louis,
MO, USA, 16 μg in 3 μl 0.9% saline solution containing 0.05% ascorbic
acid) into the rightmedial forebrain bundle at the following coordinates
relative to the bregma [41]: anteroposterior: 4.4 mm; lateral: 1.2 mm;
and dorsoventral: 8.2 mm. In rats, the 6-OHDA-induced injury to the
dopaminergic neurons was tested with three different behavioral
tests: open ﬁeld test, apomorphine-induced rotational behavior and
the stepping test.
Mice received two injections (2 μl each) of 6-OHDA into the striatum
unilaterally (right) or bilaterally (ﬁrst site: 1.0 mm anteroposterior,
2.1 mm lateral and 2.9 mm dorsoventral; second site: 0.3 mm
anteroposterior, 2.3 mm lateral and 2.9 mm dorsoventral). In mice
with unilateral injection of 6-OHDA the apomorphine-induced rotation-
al behavior was used to estimate the dopaminergic neurons' injury.
The neurotoxin was infused at 1 μl/min in rats, and at a rate of
0.5 μl/min in mice. In both rats and mice, the cannula was left in place
for 3 min before withdrawal. The efﬁcacy of 6-OHDA-induced dopami-
nergic depletion was conﬁrmed with immunohistochemistry for tyro-
sine hydroxylase (TH) in both rats and mice. The same experimental
procedure was performed for the Sham-operated animals and the
same volume of 0.9% saline solution containing 0.05% ascorbic acid
was injected in the coordinates described above.
Behavioral analysis
Apomorphine-induced rotational behavior in rats and mice
Unilaterally 6-OHDA-lesioned rats and mice were challenged with
an acute dose of apomorphine to estimate the extent of 6-OHDA-
induced dopaminergic neuron injury 21 days post-surgery. For rats,
the rotational behavior wasmeasured for 45min [39] and only animals
presentingmore than 90 contralateral turnswere included on the study
(Fig. 2A). For mice, rotational behavior was recorded for 10 min, and
only mice that presented at least 65 contralateral rotations were ana-
lyzed in this study (data not shown). The PPI test was evaluated
7 days after the rotational test to allow apomorphine washout (Fig. 1).
Open ﬁeld test, stepping test and L-DOPA-induced AIMs in rats
Locomotor activity was measured during 5 min in a circular arena
(open ﬁeld) speciﬁc for rat (75 cm diameter) surrounded by 49-cm-
high walls made of transparent plastic. Each animal was individuallyeeks after surgery by the apomorphine-induced rotational test. Theﬁrst PPI analysis (basal)
test after 1, 7 and 14 days of L-DOPA treatment.
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experimental room illuminated by low light. Behavior in the arena
was recorded by a video camera mounted on the ceiling and relayed
to a computer equipped with a video tracking, motion analysis and be-
havior recognition system (Ethovision version 2.1, Noldus Information
Technology, Netherlands) for data acquisition. The total distance trav-
eled (cm) and the speed (cm/s) were measured by tracking the animal
in the open-ﬁeld arena (Fig. 2C and D).
The stepping test [38]was used to evaluate the forelimbakinesia and
to analyze the antiparkinsonian effect of L-DOPA in rats.With one hand,
the experimenter held the rat by the lower part of the torso with the
hind limbs lifted and one forepaw held steady along its trunk by the
hand of the experimenter. The animal was moved forward across a
table for a distance of 90 cm in 5 s three times (each forepawwas alter-
nated, and the contralateral forepawwas always tested ﬁrst). The num-
ber of adjusting steps of the weight-bearing forepaw to compensate for
the straight-ahead movement of the body were counted and averaged.
The stepping test was carried out prior to any drug administration
(pre-test) and 1 h after saline or L-DOPA administration on days 1, 7
and 14 of L-DOPA chronic treatment. The results are presented as a per-
centage of the number of adjusting steps taken with the contralateral
forelimb relative to the total number of adjusting steps. Because the
results obtained throughout the chronic treatment were similar
(p N 0.05), the obtained data were averaged (Fig. 2B).
Rats weremonitored for AIMs using a rat dyskinesia scale [10,32,57].
The rats were individually placed in transparent plastic cylinders and
videotaped for 1 min for later analysis. Four types of AIMs were ana-
lyzed according to their topographic distribution and time incidence:
(i) axial dystonia, (ii) limb dyskinesia, (iii) orofacial dyskinesia, and
(iv) locomotive dyskinesia. Scores from 0 to 4 were assigned according
to the time of incidence of each of the four subtypes of movements an-
alyzed [10]. Scoreswere also assigned to the amplitude of axial and limb
AIMs [57]. AIMs were scored at 1, 2, 3 and 4 h after L-DOPA administra-
tion and the results are presented as the sum of the scores.
Prepulse inhibition in rats and mice
The testing was conducted simultaneously in two identical startle
response systems (Med Associates, Inc., USA) that record the amplitude
of the startle response in the PPI test. The parameters of PPI session for
mice and rats were previously described [27,28]. Brieﬂy, a continuous
acoustic signal provided a background white noise level of 65 dB. This
signal was interrupted by the stimulus presentations. The pulse (pulse
alone) refers to a burst of white noise of 105 dB with a rise/decay of
5 ms and duration of 20 ms for mice. For rats the pulse was a burst of
white noise of 100 dB with a rise/decay of 5 ms and duration of 40 ms.
The prepulse refers to a pure tone with an intensity of 80, 85, or
90 dB, a frequency of 7 kHz, and a duration of 10 ms for mice. For rats
the prepulse was a pure tone with an intensity of 69, 73 or 81 dB, a fre-
quency of 3 kHz, and duration of 20ms. The interval between the onset
of the prepulse and the pulse was 100ms, and the inter-stimuli interval
was 30 s for both mice and rats. The prepulse alone does not induce a
startle response. All PPI sessions startedwith a 5-min adaptation period,
followed by ten pulse presentations. These pulse-alone trials served
only to accommodate the animals to a sudden change in the stimulus
conditions and were omitted from the data analysis. The experimental
design of these pulse presentationswas used to deﬁne the baseline star-
tle response. Thereafter, the PPI modulation of the acoustic startle was
tested with 64 trials that were presented against a continuous back-
ground noise. These 64 trialswere divided into four different categories:
(1) pulse alone (P), (2) prepulse alone (PP), (3) prepulse plus pulse
(PP + P), and (4) no stimulus. The level of PPI was determined by
expressing the prepulse plus pulse startle amplitude as a percentage
of the pulse-alone startle amplitude according to the following formula:
%PPI= 100− (100 × PP+ P/P). Using this formula, a 0% value denotes
no difference between the startle reﬂex response to the pulse alone
and to the startle reﬂex response to the prepulse plus pulse and thusindicates no PPI. A low percentage score indicates a PPI deﬁcit. The star-
tle magnitude was calculated as an average of the “startle pulse alone”
trials. We exclude one rat from PPI analyses because this animal did
not corresponded to the apomorphine-induced rotational behavior
criteria [39]. We do not exclude any mice to the PPI analyses.
Sound and platform calibration. The cages were calibrated daily before
the tests were started to ensure equal sensitivity of both response
platforms and sound throughout the test periods. The sound levels
were calibrated (±1 dB) using the scale of a sound lever meter. The
platform calibration was performed by adjusting the gain on the load
cell ampliﬁer to 150 arbitrary units (AU) for mice, and 200 AU for rats.
Perfusion and tissue processing
Rats and mice were deeply anesthetized with urethane (1.5 g/kg,
Sigma-Aldrich, St. Louis, MO, USA) and rapidly perfused transcardially
with cold 0.9% saline solution containing heparin (200 μl of heparin
25,000 UI per liter of solution) and sodium nitrite (1 g/l solution).
Animals were then immediately perfused with 4% paraformaldehyde
(PFA; pH7.4; Sigma-Aldrich, St. Louis,MO, USA). Brainswere immediate-
ly removed, post-ﬁxed in 4% paraformaldehyde for 2 h and cryoprotected
in 30% sucrose solution. Brains were quickly frozen in isopentane
(−40 °C, Sigma-Aldrich, St. Louis, MO, USA) and stored at−80 °C until
histological processing. Coronal sections (25 μm) were processed in a
freezing microtome (Leica, model CM1850) throughout the rostro-
caudal extent of the striatum and substantia nigra compacta.
Immunohistochemistry
Immunohistochemistry was performed using a standard peroxidase-
basedmethod [22]. Sections were incubated overnight at room tempera-
turewith the primary antibody: rabbit anti-TH (1:4000, Pel Freez, 01,229,
USA for rats; 1:500; N15 Santa Cruz Biotechnology, formice), followed by
2hof incubationwith anti-rabbit biotinylated secondary antibody (1:250,
Vectastain, Vector Laboratories, USA). Sections were developed using
diaminobenzidine (Sigma-Aldrich, St. Louis, MO, USA) as the chromogen.
The slices were mounted on slides and coverslipped for microscopic
observations.
TH quantiﬁcation
The density of TH labelingwas examined at three rostrocaudal levels
within the striatumand substantia nigra compacta In the striatum,mea-
surements were taken in the dorsolateral and dorsomedial quadrants.
Because there were no signiﬁcant differences of TH density across
these quadrants and levels, the results obtained were averaged. Images
were captured from mice striatum (Bregma 1.10 mm to −1.22 mm)
and at the level of the substantia nigra pars compacta (Bregma
−3.08 mm; [18]) by a video camera (Leica DFC420) coupled to a light
microscope (Leica DMRB) and were transmitted to a computer
equipped with an image analysis program (Leica Application Suite, ver-
sion 3.0.4) for light and color adjustments. Analyses were performed in
gray scale images (0.16mm2) using the program ImageJ (version 1:46 J;
http://www.rsbweb.nih.gov/ij/). The data are expressed as the mean ±
SEM of relative optical density units [36]. Background was removed by
subtracting values obtained from regions without positive staining.
Statistical analysis
The behavioral tests for lesion screening (open ﬁeld test,
apomorphine-induced rotational behavior and the stepping test) and
the startle response were compared in Sham-operated and 6-OHDA-
lesioned groups with a “t” test. AIMs, the stepping test, PPI and acoustic
startle response throughout the L-DOPA chronic treatmentwere evaluat-
ed by repeatedmeasures ANOVA,with the lesion status (i.e., Sham-lesion
or 6-OHDA-lesion) as in-between factor, and the prepulse intensities or
the L-DOPA treatment as within factors. In the L-DOPA-treated rats this
analysis was performed for all prepulse intensities. In the case of signiﬁ-
cant main effects the repeated measures ANOVA was followed by paired
Fig. 2. The effects of 6-OHDA-induced depletion of dopaminergic neurons on nigrostriatal
pathway. A–D: The effects of 6-OHDA-induced depletion of dopaminergic neurons were
tested with three different behavioral tests: (A) apomorphine-induced rotational behav-
ior, (B) stepping test and (C and D) open ﬁeld test. The severe dopaminergic depletion
of dopaminergic neurons in the substantia nigra induced robust contralateral rotational
behavior by apomorphine (A) and impaired stepping test (B). The two parameters mea-
sured on the open ﬁeld test (C— distance and D— speed) were equally reduced in severe
6-OHDA-lesioned animals. Data aremean± SEM of Sham-lesioned (n= 6) and 6-OHDA-
lesioned animals (n=7). *p b 0.05 vs. Sham(t test). E–F: Representative sections showing
TH immunocytochemical staining in the striatum and substantia nigra compacta after
the right medial forebrain bundle 6-OHDA lesion. The 6-OHDA-ipsilateral side shows a
complete depletion of TH-immunoreactivity. AcbC, nucleus accumbens core; AcbSh,
nucleus accumbens shell; SNc, substantia nigra compacta; VTA, ventral tegmental area.
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was performed through an independent “t” test in the bilateral lesioned
mice. Paired “t” testwas used for unilateral lesionedmice. Statistical anal-
ysis was performed with the signiﬁcance set at p b 0.05 (SPSS, SPSS Inc.).
Data are presented as the mean ± SEM.
Experimental design
Effects of 6-OHDA-lesion on PPI in rats and mice. At 28 days post-surgery,
unilaterally Sham-operated (n= 6) and 6-OHDA-lesioned rats (n= 7)
were tested on PPI paradigm. At the same time post-surgery, Sham-
operated (unilateral microinjection, n = 8; bilateral microinjection,
n=8) and 6-OHDA-lesionedmice (unilateralmicroinjection, n=8; bi-
lateral microinjection, n = 8) were also tested on PPI (Fig. 1).
AIMs development during the course of L-DOPA administration to 6-OHDA-
lesioned rats. 6-OHDA-lesioned and Sham-operated rats received L-DOPA
(30 mg/kg plus benserazide-HCl 7.5 mg/kg, once daily, gavage) during
14 days starting at 30 days after surgery (Fig. 1). The scores for AIMs
and the stepping test were assigned throughout the L-DOPA treatment
on days 1, 7 and 14 as described elsewhere. At the end of the experiment,
the brains were processed for TH immunohistochemistry to conﬁrm the
extent of dopaminergic depletion.
Effects of L-DOPA treatment on PPI in rats and mice. The effect of L-DOPA
treatment was evaluated in the PPI response in rats. We evaluated the
effect of acute (day 1), subchronic (day 7) and chronic (day 14)
L-DOPA treatment (Fig. 1). Due to the incidence of AIMs and rotational
behavior following L-DOPA administration, rats were tested for PPI only
when these behaviors were no longer present (approximately 3 h after
L-DOPA treatment).
Results
TH quantiﬁcation
Immunohistochemistry analyses conﬁrmed that 6-OHDA microin-
jection into the medial forebrain bundle induced a massive N90% de-
crease of the TH-immunoreactivity in both the dopaminergic nerve
terminals of the striatum and cellular bodies of the substantia nigra ip-
silateral to the lesion (Fig. 2E and F). The extension of the lesion com-
prises a decrease in TH immunoreactivity in the ventral tegmental
area, septum lateral and nucleus accumbens. The microinjection of 6-
OHDA in the dorsal striatum induced a partial reduction of TH immuno-
reactivity in the striatum and substantia nigra pars compacta; unilateral
or bilateral (Fig. 3). The analyses of TH at the nucleus accumbens core
and shell conﬁrmed that these regions were entirely preserved in
mice injected with 6-OHDA (data not shown).
Effects of 6-OHDA-induced parkinsonism on PPI and startle response in rats
and mice
Rats
In rats, there is a trend (Fig. 4A) for 6-OHDA unilateral lesion to im-
pair PPI response (group main effect [F1,11 = 3.73, p = 0.080], and an
interaction between the variable group and prepulse intensity
[F2,22 = 2.71, p = 0.088]). There is no main effect of prepulse intensity
[F2,22 = 1.21, p = 0.315]. Individual comparisons showed PPI impair-
ment at prepulse intensities of 69 and 81 dB (“t” test, Fig. 4A). The startle
response amplitude was not modiﬁed by unilateral 6-OHDA-induced
severe dopamine depletion in rats (Fig. 4B).
Mice
The 6-OHDA unilateral striatal lesion did not modify the PPI re-
sponse (Fig. 5A). The analysis of variance revealed a signiﬁcant effect
of prepulse intensity [F2,28 = 16.29, p b 0.001] but not of group[F1,14 = 0.49, p = 0.493] or an interaction between prepulse intensity
and group [F2,28= 0.067, p= 0.935]. Similarly, the 6-OHDA bilateral le-
sion did not signiﬁcantly modify the PPI response in mice (Fig. 5B). The
analysis of variance revealed a signiﬁcant effect of prepulse intensity
[F2,28 = 8.46, p = 0.001] but not a main effect of group [F1,14 = 2.14,
p= 0.165]. There was a signiﬁcant interaction between prepulse inten-
sity and group [F2,28 = 5.87, p = 0.007].
The startle response amplitudewas notmodiﬁed by 6-OHDA inmice
(data not shown).
Effects of acute and chronic L-DOPA treatment on PPI and startle response
in rats
Time-course of L-DOPA on motor behavioral effects in 6-OHDA-lesioned
rats. Chronic administration of L-DOPA to 6-OHDA-lesioned rats over
Fig. 3. TH immunoreactivity. Percentage of remained TH positive ﬁbers in the striatum (A and B) and cellular bodies in the substantia nigra compacta (C and D) of sham and 6-OHDA-
lesioned mouse. Representative sections showing TH immunopositive staining in the unilateral (E and G) and bilateral (F and H) striatum and substantia nigra compacta after striatal
6-OHDA lesion. *p b 0.05 compared to the sham-lesioned group; n = 8 per group. Acb, nucleus accumbens; OD, optical density; SNc, substantia nigra compacta; VTA, ventral tegmental
area.
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AIMs (Fig. 6A, F2,18 = 10.23, p b 0.001) and locomotive AIMs (Fig. 6B,
F2,18 = 13.89, p b 0.001) contralateral to the side of 6-OHDA
microinjection.
Administration of L-DOPA had a signiﬁcant impact on the stepping
test and a signiﬁcant interaction for time and lesion factors was ob-
served [F3,33 = 33.67, p b 0.001] (Fig. 6C). Post-hoc analysis revealed
that 6-OHDA-lesioned animals had a marked reduction of stepping
test performance on the pre-test (before L-DOPA; ⁎⁎⁎p b 0.05 vs.
Sham). Chronic L-DOPA administration improved the stepping test
(measured 1 h after L-DOPA) performance over the entire chronic treat-
ment period (days 1, 7 and 14; p N 0.05 vs. Sham).Time-course of L-DOPA on PPI and startle response in 6-OHDA-lesioned
rats.Although L-DOPA treatment did not signiﬁcantlymodify the PPI re-
sponse in the Sham-operated group of rats, we observed a trend for a
decrease of PPI at a prepulse intensity of 69 dB (Fig. 7A).
In the 6-OHDA-lesioned group, chronic L-DOPA treatment signiﬁ-
cantly increased the PPI response at a prepulse intensity of 73 dB
(paired “t” test; p = 0.015; Fig. 7A). In this prepulse intensity the
analysis of variance revealed a signiﬁcant effect of L-DOPA treatment
[F3,33 = 2.93, p = 0.048]. No effect for group factor [F1,11 = 0.11, p =
0.745] and no interaction between treatment and group factors
[F3,33 = 1.11, p = 0.356] were observed.
L-DOPA treatment did not modify the startle response amplitude in
the Sham-operated and 6-OHDA-lesioned rats (Fig. 7B).Fig. 4. Effects of 6-OHDA severe lesion on PPI and startle response amplitude. PPI was im-
paired in rats with severe dopaminergic depletion of dopaminergic neurons (A). The star-
tle reﬂex amplitude remained unaltered (B). Data are mean ± SEM of Sham-lesioned
(n = 6) and 6-OHDA-lesioned animals (n = 7). *p b 0.05; #p = 0.055 compared to the
Sham-lesioned group.Discussion
In this study we found that a massive (N90%) 6-OHDA-induced uni-
lateral depletion of TH positive ﬁbers in the striatum of rats (dorsal and
nucleus accumbens) induced the decrease of PPI response. In severe
unilaterally 6-OHDA-lesioned rats, PPI response was impaired at
prepulse intensities of 69 and 81 dB. These effects were not related
to a general reduction of startle response that remained unaltered.
Conversely, a partial (≥40%) 6-OHDA-induced uni- or bilateral deple-
tion of TH positive ﬁbers in the dorsal but not ventral striatum (nucleus
accumbens) of mice did not induce signiﬁcant changes of PPI response.
Taken together, our data suggest that a partial degeneration of the
dorsal striatum should not be sufﬁcient to alter the function of sensori-
motor gating. Our data corroborates the hypothesis that the impairment
of the mesolimbic pathway is associated with PPI deﬁcit.
There is evidence of abnormal sensorimotor integration in PD [1]. At
least in some studies, PPI was reduced in PD patients [1,12,37,55]. PPI
disruption may be related to the cognitive impairment found in basal
ganglia disorders, as Huntington's disease [50,55], which support the
role of the striatum in the regulation of PPI in humans [54].
Recently, Zoetmulder and co-workers [59] conducted a study with
38 PD patients regarding PPI response, and the potential role of sensori-
motor processes in the cognitive function. These authors found in PD
patients either a high or low PPI response. Interestingly, the cognitive
measures (tapping attention and processing speed) were found better
in the patients with higher level of PPI [59].
In addition, PPI should be classiﬁed as a marker of the severity of
brainstemand basal ganglia dysfunction, and it could aid in the differen-
tial diagnosis between PD and the multiple system atrophy, another
condition reliant on the degeneration of the midbrain dopaminergic
system [60]. A study with ten patients with PD dementia showed an in-
termediate alteration in the PPI response [42].
There are controversial results concerning PPI response in experi-
mental models of PD. Swerdlow and co-authors [45] did not found
any important alteration in the PPI response after 6-OHDA bilateral
injection in the substantia nigra of rats. The bilateral injection of
6-OHDA in the dorsal striatum of rats also did not alter PPI response
[31]. Even though, McFarland and coworkers [34,35] found PPI impair-
ment in the rats that received 6-OHDA in the bilateral substantia
nigra. Mice treated with MPTP showed no changes in the PPI response
[30]. Similarly, the bilateral lesion of the substantia nigra with ibotenic
acid did not alter PPI response in mice [9]. In two different mice PD ge-
netic models PPI was found either impairment [56] or improvement
[23].
Fig. 5. Effects of 6-OHDA partial lesion on PPI response. In mice injected unilaterally with 6-OHDA (A; n = 8) or bilaterally (B; n = 8) in the dorsal striatum, PPI remained unaltered.
Data are mean ± SEM of Sham-lesioned and 6-OHDA-lesioned groups.
76 A.C. Issy et al. / Life Sciences 125 (2015) 71–78In rodents, PPI is regulated by cortical and subcortical structures,
such as the striatum and pallidum [51]. In rats, PPI can be modulated
by both ventral and the caudodorsal striato-pallidal circuitry [29]. Ac-
cording to that, we demonstrated that 6-OHDA-lesioned rats presented
a more extended dopaminergic lesion encompassing the core and shell
portions of nucleus accumbens as compared to mice that presented ex-
clusively a partial dorsal lesion. Since only rats presented a disruption
on PPI response, we can argue that the ventral striatum may represent
the main region in the dynamic of sensorimotor control [47].
On the other hand, the occurrence of a complex interaction between
drug-related, and disease related components has been argued regard-
ing the psychotic symptoms of PD, mainly represented through visual
hallucinations [2,17,40]. PPI disruption is sometimes classiﬁed as a
psychosis-related index [4,23]. PD patients are considered prone for
psychosis development [17]. In this regard, PPI could represent a pre-
clinical tool to predict the psychosis risk of novel PD medications [4,
23], given that dopaminergic agonists disrupt PPI in rats and humans
[48,52], and PD medications are designed to increase dopamine
signaling.
Although the effects of L-DOPA on PPI response are not completely
understood, it seems to be dose-dependent. In non-lesioned rodents,
higher doses of L-DOPA (100 or 300 mg/kg), acutely, reduced PPI
response in rats but not in mice [4]. In the same work, authors found
that the acute administration of L-DOPA 30 mg/kg, the same dose
used in the present study, 1 h before PPI test, did not cause any PPI
change in the non-lesioned rats [4]. Our results demonstrated that
chronic L-DOPA (30 mg/kg) did not induce signiﬁcant changes of PPI
response in sham-operated rats. Interestingly, chronic administration
of L-DOPA to 6-OHDA-lesioned rats increased PPI response at prepulse
intensity of 73 dB. It is already known that lowdoses of psychostimulants
might increase PPI response when baseline PPI is low [15]. However,Fig. 6. Chronic administration of L-DOPA to 6-OHDA-lesioned rats: effects on the development o
increased over the time axial, limb, orofacial AIMs scores. Post-hoc comparisons revealed a sign
day 1. A signiﬁcant difference was also observed between days 7 and 14 (#p b 0.05). (B) L-DOPA
icant increase in the locomotive AIMs scores in days 7 (***p b 0.001) and 14 (***p b 0.001) com
L-DOPA administration. (C) Chronic L-DOPA treatment improved stepping test performance in
stepping test was decreased in 6-OHDA-lesioned rats before (“Pre”) L-DOPA treatment (***p b
during days 1, 7 and 14 of chronic treatment (*p N 0.05 vs. Sham). The stepping test is presented
limb in relation to the total number of adjusting steps (performed with both ipsi- and contralawe did not ﬁnd a total correlation between lower PPI response and
L-DOPA effects.Technical limitations
Ideally, the 6-OHDA-induced complete or partial dopaminergic lesion
should have been tested in bothmice and rats. However, considering the
controversial data in the literature regarding mice and rats, similar to
what is seen in human studies, the animal species probably does not rep-
resent themain deﬁning factor. The unilateral lesion in the nigro-striatal
tract that promotes dopaminergic degeneration at the dorsal striatum
but preserves the nucleus accumbens could further add to the impor-
tance of this region to the sensorimotormodulation, aswe hypothesized.
However, the unilateral lesion is almost invariably necessary since bilat-
eral lesions result in marked adispsia and aphagia [43].Conclusion
We found abnormalities in the sensorimotor integration measured
through the PPI response in the PD experimental model. These alter-
ationswere restricted to severe unilaterally dopaminergic degeneration
in the ventral/dorsal striatum. Our data suggest a prominent role for the
nucleus accumbens in the regulation of sensorimotor gating. L-DOPA
at the dose tested, despite adverse motor effects, should not induce an
impairment of the sensorimotor response.Conﬂicts of interest
The authors declare that there are no conﬂicts of interest.f abnormal involuntarymovements (AIMs) and on stepping test performance. (A) L-DOPA
iﬁcant increase in the AIMs scores in days 7 (***p b 0.001) and 14 (*p b 0.05) compared to
increased over the time locomotive AIMs scores. Post-hoc comparisons revealed a signif-
pared to day 1. AIMs are presented as the sum of the scores assigned at 1, 2, 3 and 4 h after
6-OHDA-lesioned rats. Post-hoc comparisons demonstrated that rats' performance on the
0.001 vs. Sham). Chronic L-DOPA induced a signiﬁcant improvement on the stepping test
as the percentage of the number of adjusting steps performedwith the contralateral fore-
teral forelimb). Data are mean ± SEM (one or two-way repeated measures ANOVA).
Fig. 7. Effects of L-DOPA treatment on PPI and startle response amplitude. Sham-lesioned (n=6) and6-OHDA-lesioned rats (n=7)were evaluated 3 h after L-DOPA oral treatment at 1, 7
and 14 days, corresponding to acute, subchronic or chronic treatment. Bars for basal conditions were duplicated from Fig. 4. Data are mean± SEM. *p b 0.05 compared to basal condition,
(paired test t).
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